Correlates of insulin resistance in older individuals with and without kidney disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 2814-2819

  Landau, Michael ^a   Kurella Tamura, Manjula ^b   Shlipak, Michael G ^c,d   Kanaya, Alka ^d   Strotmeyer, Elsa ^e   Koster, Annemarie ^f,g   Satterfield, Suzanne ^h   Simsonick, Eleanor M ^f   Goodpaster, Bret ⁱ   Newman, Anne B ^e,i   Fried, Linda F ^e,i,j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c General Internal Medicine Section   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

chronic kidney disease; cystatin C; insulin resistance; subcutaneous fat

Indexed keywords

ADIPONECTIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; AGED; ARTICLE; BODY FAT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MUSCLE TISSUE; NEGRO; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SEX;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CYSTATIN C; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LIPOPROTEINS, HDL; MALE; PROGNOSIS; RESISTIN; SURVIVAL RATE;

EID: 80053210629     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq817     Document Type: Article

References (45)

1. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752 (Pubitemid 41532612)
2. Rowe JW, Minaker KL, Pallotta JA et al. Characterization of the IR of aging. J Clin Invest 1983; 71: 1581-1587
3. McCaleb ML, Wish JB, Lockwood DH. IR in chronic renal failure. Endocr Res 1985; 11: 113-125
4. Dzurik R, Spustova V, Janekova K. The prevalence of IR in kidney disease patients before the development of renal failure. Nephron 1995; 69: 281-285
5. Eidemak I, Feldt-Rasmussen B, Kanstrup IL et al. IR and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995; 38: 565-572
6. Fliser D, Pacini G, Engelleiter R et al. IR and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347 (Pubitemid 28316896)
7. Kato Y, Hayashi M, Ohno Y et al. Mild renal dysfunction is associated with IR in chronic glomerulonephritis. Clin Nephrol 2004; 54: 366-373
8. Dengel DR, Goldberg AP, Mayuga RS et al. IR, elevated glomerular filtration fraction, and renal injury. Hypertension 1996; 28: 127-132 (Pubitemid 26231101)
9. Chen J, Muntner P, Hamm LL et al. IR and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477 (Pubitemid 36150872)
10. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with IR. Kidney Int 2006; 69: 596-604 (Pubitemid 43164455)
11. Becker B, Kronenberg F, Kielstein JT et al. Renal IR syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098 (Pubitemid 41710320)
12. Tamei N, Ogawa T, Ishida H et al. Relationship of high-molecular weight adiponectin levels to visceral fat accumulation in hemodialysis patients. Intern Med 2010; 49: 299-305
13. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281 (Pubitemid 38037514)
14. Ramos LF, Shintani A, Himmelfarb J et al. Determinants of plasma adiponectin levels in nondiabetic subjects with moderate to severe chronic kidney disease. J Ren Nutr 2009; 19: 197-203
15. Shoji T, Shinohara K, Hatsuda S et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 2005; 54: 330-334 (Pubitemid 40250092)
16. Taskapan MC, Taskapan H, Sahin I et al. Serum leptin, resistin and lipid levels in patients with end-stage renal failure with regard to dialysis modality. Ren Fail 2007; 29: 147-154
17. Mather KJ, Hunt AE, Steinberg HO et al. Repeatability characteristics of simple indices of IR: implications for research applications. J Clin Endocrinol Metab 2001; 86: 5457-5464 (Pubitemid 33070275)
18. Stevens LA, Coresh J, Schmid CH et al. Estimating GFR using serum cystatin c alone and in combination with serum creatinine: a pooled analysis of 3418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406 (Pubitemid 351273480)
19. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 105: 604-612
20. Visser M, Pahor M, Tylavsky F et al. One-and two-year change in body composition as measured by DXA in a population-based cohort of older men and women. J Appl Physiol 2003; 94: 2368-2374 (Pubitemid 36605299)
21. Defronzo RA, Alvestrand A, Smith D et al. IR in uremia. J Clin Invest 1981; 67: 563-568
22. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140 (Pubitemid 41716445)
23. Ryu S, Chang Y, Woo HY et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis 2009; 53: 59-69
24. Nerpin E, Riserus U, Ingelsson E et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 2008; 31: 1550-1555
25. Aksentijevi D, Bhandari S, Seymour AL. IR and altered glucose transporter 4 expression in experimental uremia. Kidney Int 2009; 75: 711-718
26. Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006; 70: 453-459 (Pubitemid 44141571)
27. Kobayashi S, Maesato K, Moriya H et al. IR in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-280
28. Defronza RA, Alvestrand A. Glucose intolerance in uremia: site and mechanism. Am J Clin Nutr 1980; 33: 1439-1445
29. Kohrt WM, Kirwan JP, Staten MA et al. IR in aging is related to abdominal obesity. Diabetes 1993; 42: 273-281
30. Ross R, Freeman J, Hudson R et al. Abdominal obesity, muscle composition, and IR in premenopausal women. J Clin Endocrinol Metab 2002; 87: 5044-5051 (Pubitemid 35316344)
31. Wagenknecht LE, Langefeld CD, Scherzinger AL et al. Insulin sensitivity, insulin secretion, and abdominal fat: the IR Atherosclerosis Study (IRAS) Family Study. Diabetes 2003; 52: 2490-2496 (Pubitemid 37210536)
32. Abate N, Garg A, Peshock RM et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995; 96: 88-98
33. Goodpaster BH, Thaete FL, Simoneau JA et al. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579-1585 (Pubitemid 27411233)
34. Hayashi T, Boyko EJ, McNeely MJ et al. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future IR in Japanese Americans. Diabetes 2008; 57: 1269-1275
35. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant 2008; 23: 3041-3046
36. Kern PA, Di Gregorio GB, Lu T et al. Adiponectin expression from human adipose tissue: relation to obesity, IR, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-1785 (Pubitemid 36792470)
37. Kraus LM, Traxinger R, Kraus AP. Uremia and IR: N-carbamoylasparagine decreases insulin-sensitive glucose uptake in rat adipocytes. Kidney Int 2004; 65: 881-887 (Pubitemid 38251063)
38. Axelsson J, Rashid Qureshi A, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229 (Pubitemid 41350682)
39. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996; 50: 1928-1935 (Pubitemid 26417536)
40. Axelsson J, Stenvinkel P. Role of fat mass and adipokines in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 25-31 (Pubitemid 350295193)
41. Yamauchi T, Kadowaki T. Physiologic and pathophysiologic roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes 2008; 32: S13-S18
42. Hajer G, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes and vascular diseases. Eur Heart J 2008; 29: 2959-2971
43. Shen YY, Peake PW, Charlesworth JA. Review article: adiponectin: its role in kidney disease. Nephrology 2008; 13: 528-534
44. Fried LF, Boudreau R, Lee JS et al. Kidney function as a predictor of loss of lean mass in older adults: Health, Aging and Body Composition Study. J Am Geriatr Soc 2007; 55: 1578-1584 (Pubitemid 47508517)
45. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess IR in renal failure patients. Nephron 2001; 89: 348-349 (Pubitemid 34701771)